Compare FSUN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | AAPG |
|---|---|---|
| Founded | 1892 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2017 | 2024 |
| Metric | FSUN | AAPG |
|---|---|---|
| Price | $37.99 | $15.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $45.75 | $44.50 |
| AVG Volume (30 Days) | ★ 340.5K | 4.4K |
| Earning Date | 10-26-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.33 | $18.59 |
| Revenue Next Year | $14.94 | $120.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.95 | $14.46 |
| 52 Week High | $42.34 | $35.86 |
| Indicator | FSUN | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 46.20 |
| Support Level | $37.67 | $14.50 |
| Resistance Level | $40.43 | $16.34 |
| Average True Range (ATR) | 0.85 | 0.57 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 22.86 | 31.05 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.